
|Articles|February 1, 2001
- Pharmaceutical Executive-02-01-2001
- Volume 0
- Issue 0
Neurology's Broader Promise: An Exclusive Interview with Christopher Reeve
Author(s)Wayne Koberstein
During our conversation, Reeve pushes an even broader agenda: getting pharmaceutical companies to realize the huge market potential in spinal-cord research for a host of neurological conditions. He implores companies to put their attention, and their investment, into enterprises that are creating breakthroughs in new technologies promising wide therapeutic application.
Advertisement
Articles in this issue
over 24 years ago
The Top Ten Marketing Challenges in Neurologyover 24 years ago
A Right to Dreamover 24 years ago
Woman With a Mission: Pfizer's Lisa Egbuonu-DavisNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
2
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
3
GSK Enters $745 Million Worldwide Exclusive License Agreement with Empirico for Clinical-Stage First-In-Class Oligonucleotide Candidate
4
FDA Approves Single-Injection, Once-Monthly Maintenance Regimen for Lilly’s Omvoh in Ulcerative Colitis
5





